JP2022549519A - 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節 - Google Patents

標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節 Download PDF

Info

Publication number
JP2022549519A
JP2022549519A JP2022520089A JP2022520089A JP2022549519A JP 2022549519 A JP2022549519 A JP 2022549519A JP 2022520089 A JP2022520089 A JP 2022520089A JP 2022520089 A JP2022520089 A JP 2022520089A JP 2022549519 A JP2022549519 A JP 2022549519A
Authority
JP
Japan
Prior art keywords
crispr
bacteroides
nucleic acid
nuclease
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520089A
Other languages
English (en)
Japanese (ja)
Inventor
イーストランド，エリック
ジャン，ジーガン
ディ デイビス，グレゴリー
ウォルター ベラー，ザッカリー
アイバン ゴードン，ジェフリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Aldrich Co LLC
Washington University in St Louis WUSTL
Original Assignee
Sigma Aldrich Co LLC
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co LLC, Washington University in St Louis WUSTL filed Critical Sigma Aldrich Co LLC
Publication of JP2022549519A publication Critical patent/JP2022549519A/ja
Priority to JP2024087359A priority Critical patent/JP2024116193A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022520089A 2019-09-30 2020-09-29 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節 Pending JP2022549519A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024087359A JP2024116193A (ja) 2019-09-30 2024-05-29 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962908130P 2019-09-30 2019-09-30
US62/908,130 2019-09-30
US201962909078P 2019-10-01 2019-10-01
US62/909,078 2019-10-01
US202063052825P 2020-07-16 2020-07-16
US63/052,825 2020-07-16
PCT/US2020/053304 WO2021067291A1 (en) 2019-09-30 2020-09-29 Modulation of microbiota compositions using targeted nucleases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024087359A Division JP2024116193A (ja) 2019-09-30 2024-05-29 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節

Publications (1)

Publication Number Publication Date
JP2022549519A true JP2022549519A (ja) 2022-11-25

Family

ID=72896108

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520089A Pending JP2022549519A (ja) 2019-09-30 2020-09-29 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節
JP2024087359A Pending JP2024116193A (ja) 2019-09-30 2024-05-29 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024087359A Pending JP2024116193A (ja) 2019-09-30 2024-05-29 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節

Country Status (10)

Country Link
US (1) US20210095273A1 (https=)
EP (1) EP4038185A1 (https=)
JP (2) JP2022549519A (https=)
KR (1) KR20220051259A (https=)
CN (1) CN114929873A (https=)
AU (1) AU2020357816A1 (https=)
BR (1) BR112022005831A2 (https=)
CA (1) CA3152931A1 (https=)
IL (1) IL291509A (https=)
WO (1) WO2021067291A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127209A1 (en) * 2019-12-17 2021-06-24 Sigma-Aldrich Co. Llc Genome editing in bacteroides
CN116004688A (zh) * 2021-10-21 2023-04-25 中国科学院深圳先进技术研究院 肠道菌拟杆菌的基因编辑方法与应用
US20250034579A1 (en) * 2021-12-07 2025-01-30 Cornell University Methods and compositions for genetically modifying human gut microbes
KR20240172712A (ko) * 2023-05-31 2024-12-10 한국생명공학연구원 아커만시아 뮤시니필라 tars를 발현 및 분비하도록 설계된 프로바이오틱스 및 이의 제조를 위한 벡터

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
JP2017512500A (ja) * 2014-03-25 2017-05-25 ギンゴー バイオワークス， インコーポレイテッド 細胞工学のための方法および遺伝システム
US20180163216A1 (en) * 2015-06-10 2018-06-14 Massachusetts Institute Of Technology Gene expression in bacteroides
JP2018515138A (ja) * 2015-05-06 2018-06-14 エスエヌアイピーアール・テクノロジーズ・リミテッドＳｎｉｐｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 微生物集団の改変および微生物相の修飾

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5070051B2 (ja) * 2004-06-07 2012-11-07 クー バイオロジックス インク． 癌を治療するための細菌組成物
CA2682242A1 (en) * 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium longum strain
US20110281762A1 (en) * 2010-05-13 2011-11-17 Sonnenburg Justin L High throughput screening for anaerobic microorganisms
EP3241902B1 (en) * 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2015006294A2 (en) * 2013-07-10 2015-01-15 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
US11408007B2 (en) * 2014-09-26 2022-08-09 Yale University Compositions and methods for biocontainment of microorganisms
JP6886142B2 (ja) * 2017-01-04 2021-06-16 国立大学法人 新潟大学 腸内細菌叢改善剤及びその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
JP2017512500A (ja) * 2014-03-25 2017-05-25 ギンゴー バイオワークス， インコーポレイテッド 細胞工学のための方法および遺伝システム
JP2018515138A (ja) * 2015-05-06 2018-06-14 エスエヌアイピーアール・テクノロジーズ・リミテッドＳｎｉｐｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 微生物集団の改変および微生物相の修飾
US20180163216A1 (en) * 2015-06-10 2018-06-14 Massachusetts Institute Of Technology Gene expression in bacteroides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CELL SYSTEMS, vol. 1, JPN6023021527, 2015, pages 62 - 71, ISSN: 0005249391 *
DATABASE UNIPROT， [ONLINE] ，ACCESSION NO.Q8A7M5, JPN6023021526, 1 June 2003 (2003-06-01), ISSN: 0005249392 *
FRONTIERS IN MICROBIOLOGY, vol. vol.8,article 2234, JPN6023021529, 2017, pages 1 - 21, ISSN: 0005071967 *

Also Published As

Publication number Publication date
BR112022005831A2 (pt) 2022-06-21
WO2021067291A1 (en) 2021-04-08
US20210095273A1 (en) 2021-04-01
CA3152931A1 (en) 2021-04-08
EP4038185A1 (en) 2022-08-10
KR20220051259A (ko) 2022-04-26
CN114929873A (zh) 2022-08-19
AU2020357816A1 (en) 2022-04-14
IL291509A (en) 2022-05-01
JP2024116193A (ja) 2024-08-27

Similar Documents

Publication Publication Date Title
Neil et al. High‐efficiency delivery of CRISPR‐Cas9 by engineered probiotics enables precise microbiome editing
JP2024116193A (ja) 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節
Dong et al. Exploiting a conjugative CRISPR/Cas9 system to eliminate plasmid harbouring the mcr-1 gene from Escherichia coli
JP2021000092A (ja) 細胞工学のための方法および遺伝システム
CN107208070B (zh) 细菌基因的靶向消除
CN108026536A (zh) 使用crispr核酸筛选细菌、古细菌、藻类和酵母的方法
US20250354158A1 (en) Cis conjugative plasmid system
US11591604B2 (en) Gene expression in Bacteroides
JP2024125308A (ja) バクテロイデスにおけるゲノム編集
Sheng et al. Engineering conjugative CRISPR-Cas9 systems for the targeted control of enteric pathogens and antibiotic resistance
EP3541942B1 (en) Conjugative vectors selectable by fructooligosaccharides
Álvarez-Martín et al. Improved cloning vectors for bifidobacteria, based on the Bifidobacterium catenulatum pBC1 replicon
Rodriguez et al. Targeted gene disruption in Francisella tularensis by group II introns
Van Allen et al. New vectors and optimal conditions for allelic exchange in hypervirulent Klebsiella pneumoniae
Vento et al. Genome editing with Cas9 in lactobacilli
Al-Rubaye et al. Molecular detection of virulent exoU mutation of Pseudomonas aeruginosa isolated from wound and burn samples.
JP6412865B2 (ja) ビフィドバクテリウム・ブレーベ株特異的遺伝子
Shi et al. Engineering and characterization of a symbiotic selection-marker-free vector-host system for therapeutic plasmid production
Friess et al. A CRISPRi gene regulation system for bifidobacteria
Gurtler et al. Genome engineering
Song et al. Establishment of a CRISPR interference (CRISPRi) system in Limosilactobacillus reuteri AR673
Walker-Sünderhauf Removal of antimicrobial resistance genes from bacterial strains and communities using CRISPR-Cas9
WO2024096123A1 (ja) 遺伝子が改変された微生物およびその生産方法
Yang et al. Genomic integration and expression of the Aggregatibacter actinomycetemcomitans catalase gene in Aggregatibacter aphrophilus
Wan An experimental investigation into the mechanisms of bacterial evolution

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502